Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents

MT Newswires Live07-16 20:16

Arbutus Biopharma (ABUS) and its licensee Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), said Thursday they have filed three international patent infringement lawsuits against Pfizer (PFE), BioNTech (BNTX) over lipid nanoparticle technology used in mRNA COVID-19 vaccines.

The companies said they are seeking monetary damages and permanent injunctions covering Pfizer-BioNTech's COVID-19 vaccines and other allegedly infringing products.

The new actions expand their existing US patent litigation in New Jersey involving five patents, they said.

Separately, Arbutus said it received about $178 million from Moderna (MRNA) on July 8 as its part of a global patent settlement and expects to receive a dividend from Genevant's parent in Q3.

The company said it plans to return capital to shareholders through share repurchases of up to $230 million starting in Q3.

Arbutus Biopharma shares were 3.7% higher in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651417554?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651417554","market":"us","top_or_hot":-1,"title":"Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ABUS\">Arbutus Biopharma</a> (ABUS) and its licensee Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), said Thursday they have filed three international patent infringement lawsuits against Pfizer (PFE), BioNTech (BNTX) over lipid nanoparticle technology used in mRNA COVID-19 vaccines.</p><p>The companies said they are seeking monetary damages and permanent injunctions covering Pfizer-BioNTech's COVID-19 vaccines and other allegedly infringing products.</p><p>The new actions expand their existing US patent litigation in <a href=\"https://laohu8.com/S/NJR\">New Jersey</a> involving five patents, they said.</p><p>Separately, Arbutus said it received about $178 million from <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> (MRNA) on July 8 as its part of a global patent settlement and expects to receive a dividend from Genevant's parent in Q3.</p><p>The company said it plans to return capital to shareholders through share repurchases of up to $230 million starting in Q3.</p><p>Arbutus Biopharma shares were 3.7% higher in premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-16 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ABUS\">Arbutus Biopharma</a> (ABUS) and its licensee Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), said Thursday they have filed three international patent infringement lawsuits against Pfizer (PFE), BioNTech (BNTX) over lipid nanoparticle technology used in mRNA COVID-19 vaccines.</p><p>The companies said they are seeking monetary damages and permanent injunctions covering Pfizer-BioNTech's COVID-19 vaccines and other allegedly infringing products.</p><p>The new actions expand their existing US patent litigation in <a href=\"https://laohu8.com/S/NJR\">New Jersey</a> involving five patents, they said.</p><p>Separately, Arbutus said it received about $178 million from <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> (MRNA) on July 8 as its part of a global patent settlement and expects to receive a dividend from Genevant's parent in Q3.</p><p>The company said it plans to return capital to shareholders through share repurchases of up to $230 million starting in Q3.</p><p>Arbutus Biopharma shares were 3.7% higher in premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651417554","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651417554","pubTimestamp":1784204172,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arbutus Biopharma  and its licensee Genevant Sciences, a subsidiary of Roivant Sciences , said Thursday they have filed three international patent infringement lawsuits against Pfizer , BioNTech  over lipid nanoparticle technology used in mRNA COVID-19 vaccines.The companies said they are seeking monetary damages and permanent injunctions covering Pfizer-BioNTech's COVID-19 vaccines and other allegedly infringing products.The new actions expand their existing US patent litigation in New Jersey involving five patents, they said.Separately, Arbutus said it received about $178 million from Moderna  on July 8 as its part of a global patent settlement and expects to receive a dividend from Genevant's parent in Q3.The company said it plans to return capital to shareholders through share repurchases of up to $230 million starting in Q3.Arbutus Biopharma shares were 3.7% higher in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","SG9999002232.USD":"Allianz Global High Payout USD","MRNA":"Moderna, Inc.","IDNA":"iShares Genomics Immunology and Healthcare ETF","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","PFE":"辉瑞","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LGHT":"LANGAR GLOBAL HEALTHTECH ETF","BK4007":"制药","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4551":"寇图资本持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","LU2596442595.SGD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (SGDHDG) INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4588":"碎股","BK4501":"段永平概念","LU0058720904.USD":"联博国际健康护理基金A","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","OZEM":"Roundhill GLP-1 & Weight Loss ETF","BK4534":"瑞士信贷持仓","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4139":"生物科技","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","ROIV":"Roivant Sciences Ltd.","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","GNOM":"Global X Genomics & Biotechnology ETF","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4550":"红杉资本持仓","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","MRNX":"Defiance Daily Target 2X Long MRNA ETF","BK4535":"淡马锡持仓","MRNY":"MRNA期权收益策略ETF-YieldMax","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","WDNA":"WisdomTree BioRevolution Fund","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4592":"伊斯兰概念","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","ABUS":"Arbutus Biopharma Corporation","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BNTX":"BioNTech SE"},"translate_title":"Arbutus Biopharma、Genevant 起诉辉瑞、BioNTech 脂质纳米颗粒专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGHT":0.6,"ROIV":1.86,"MRNA":1.85,"BNTX":1.92,"PTH":0.6,"WDNA":0.6,"PFE":1.93,"MRNY":0.6,"OZEM":0.6,"MRNX":0.6,"GNOM":0.6,"IDNA":0.6,"ABUS":1.98},"content_text":"Arbutus Biopharma (ABUS) and its licensee Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), said Thursday they have filed three international patent infringement lawsuits against Pfizer (PFE), BioNTech (BNTX) over lipid nanoparticle technology used in mRNA COVID-19 vaccines.The companies said they are seeking monetary damages and permanent injunctions covering Pfizer-BioNTech's COVID-19 vaccines and other allegedly infringing products.The new actions expand their existing US patent litigation in New Jersey involving five patents, they said.Separately, Arbutus said it received about $178 million from Moderna (MRNA) on July 8 as its part of a global patent settlement and expects to receive a dividend from Genevant's parent in Q3.The company said it plans to return capital to shareholders through share repurchases of up to $230 million starting in Q3.Arbutus Biopharma shares were 3.7% higher in premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651417554","isCrawlerRequest":true}